|
Stage 4S neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Integrating anti-MYCN ChIP-seq and gene expression profiles of neuroblastoma patients revealed the metabolic enzymes, MTHFD2 and PAICS, required for one-carbon metabolism and purine biosynthesis were concomitantly upregulated, which were more susceptible to metastatic neuroblastoma.
|
31624245 |
2019 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
A total of 26 patients with refractory (n = 5), metastatic relapsed (n = 20), or locally relapsed MYCN-positive (n = 1) NBL received a median of 17 × 10<sup>6</sup>/kg T/B cell-depleted CD34<sup>+</sup> stem cells with 68 × 10<sup>3</sup>/kg residual T cells and 107 × 10<sup>6</sup>/kg natural killer cells.
|
29307718 |
2018 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
|
26683771 |
2016 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a neonate with an adrenal stage 4S neuroblastoma with a small focus of MYCN-amplified cells within a nonamplified background.
|
23528904 |
2014 |
|
Stage 4S neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overexpression of N-Myc leads to transcriptional activation and an increase in NB cell proliferation.
|
24403858 |
2013 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumors with MYCN amplification show a lower chromosome instability compared to MYCN single-copy NBs (P = .0008), dominated by 17q gain and 1p loss.
|
23019414 |
2012 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).
|
22146831 |
2011 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We could not confirm the presence of a specific methylation profile in disseminated neuroblastoma tumour cells, but a high accumulation of epigenetic events in those cells is associated with a high risk of relapse, independently of MYCN amplification.
|
20140741 |
2010 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
An asymptomatic 11-week-old male received no treatment after he was classified as having a suspected atypical form of MYCN-nonamplified hyperdiploid stage 4S neuroblastoma (NB), with masses in an adrenal gland, subcutaneous tissues, and the falx cerebri.
|
19711437 |
2009 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYCN-non-amplified metastatic neuroblastoma with good prognosis and spontaneous regression: a molecular portrait of stage 4S.
|
19383347 |
2008 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We describe a 4-week-old neonate with MYCN-amplified stage 4S NB complicated by gross hepatomegaly causing rapidly progressive respiratory, hepatic, and renal failure.
|
15926157 |
2006 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Children 12 to 18 months old with metastatic NB had favorable outcomes with high-dose therapy if their tumors were hyperdiploid and lacked MYCN amplification.
|
16116152 |
2005 |
|
Stage 4S neuroblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Overall, our data indicate that MYCN overexpression increment contributes to the acquired drug resistance that occurs throughout the NB metastatic process.
|
12819037 |
2003 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MYCN gain and MYCN amplification in a stage 4S neuroblastoma.
|
12645655 |
2003 |
|
Stage 4S neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report, for the first time, a rearrangement within the MYCN coding region in a metastatic neuroblastoma in a 3-year-old boy with MYCN amplification in his primary tumor.
|
11385318 |
2001 |
|
Stage 4S neuroblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Use of a prognostic staging system based on tumor cell ploidy, augmented with the NMYC gene copy number and serum level of lactate dehydrogenase, would very likely improve the treatment of infants with unresectable or metastatic neuroblastoma.
|
9060959 |
1997 |
|
Stage 4S neuroblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Risk estimation of high discriminating power is, therefore, possible for patients with localised and metastatic neuroblastoma using stage and MYCN.
|
7576963 |
1995 |